Agomelatine: A novel melatonergic antidepressant
2010

Agomelatine: A New Antidepressant

Sample size: 711 publication Evidence: moderate

Author Information

Author(s): Manikandan S

Primary Institution: Indira Gandhi Medical College and Research Institute

Hypothesis

Can agomelatine effectively treat major depression?

Conclusion

Agomelatine is a novel antidepressant that shows potential but requires further testing to fully understand its real-world effects.

Supporting Evidence

  • Agomelatine is an agonist at melatonergic MT1 and MT2 receptors and an antagonist at serotonin 5HT2C receptor.
  • Short-term trials showed significant improvement in depression symptoms compared to placebo.
  • A long-term trial indicated a lower cumulative relapse rate for agomelatine.
  • Agomelatine has minimal effects on sexual function and is not addictive.

Takeaway

Agomelatine is a new medicine that helps people with depression by fixing their sleep patterns and mood without making them feel sleepy during the day.

Methodology

The study involved short-term and long-term clinical trials measuring the efficacy and safety of agomelatine in patients with major depression.

Limitations

The trials involved only a few hundred patients and had a maximum follow-up of 24 weeks.

Participant Demographics

Patients with major depression or bipolar II depression.

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.4103/0976-500X.72369

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication